WILLIAMSON JAMES PETER BERNARD (NL)
US20160237080A1 | 2016-08-18 | |||
US20200330405A1 | 2020-10-22 | |||
US2810723A | 1957-10-22 | |||
US20160237080A1 | 2016-08-18 |
WAGMANN LEA ET AL: "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 411, no. 19, 7 January 2019 (2019-01-07), pages 4751 - 4763, XP036827220, ISSN: 1618-2642, [retrieved on 20190107], DOI: 10.1007/S00216-018-1558-9
PASSIE T ET AL., CNS NEUROSCI THER, vol. 14, no. 4, 2008, pages 295 - 314
KREBS TS ET AL., J PSYCHOPHARMACOL, vol. 26, no. 7, July 2012 (2012-07-01), pages 994 - 1002
NICHOLS DE, ACS CHEM NEUROSCI, vol. 9, no. 10, 17 October 2018 (2018-10-17), pages 2331 - 2343
LIECHTI ME, NEUROPSYCHOPHARMACOLOGY, vol. 42, no. 11, October 2017 (2017-10-01), pages 2114 - 2127
MUTTONI S ET AL., J AFFECT DISORD, vol. 258, 1 November 2019 (2019-11-01), pages 11 - 24
SCHINDLER EAD ET AL., J PSYCHOACTIVE DRUGS, vol. 47, no. 5, 2015, pages 372 - 81
MAY JA ET AL., J MED CHEM., vol. 58, no. 22, 25 November 2015 (2015-11-25), pages 8818 - 33
YU B ET AL., J PHARMACOL EXP THER, vol. 327, no. 2, November 2008 (2008-11-01), pages 316 - 23
FAMILY N ET AL., PSYCHOPHARMACOLOGY (BERL, vol. 237, no. 3, March 2020 (2020-03-01), pages 841 - 853
BRANDT ET AL., DRUG TEST ANALYSIS, 2015
S.D. BRANDT ET AL., DRUG TEST ANALYSIS, 2019
CHRISTINA GRUMANN ET AL., DRUG TEST ANALYSIS, 2020
S.D. BRANDT ET AL., DRUG TEST ANALYSIS, 2022
S.D. BRANDT ET AL., DRUG TEST ANALYSIS, 2021
S.D. BRANDT ET AL., DRUG TEST ANALYSIS, 2017
CHRISTINA GRUMANN ET AL., JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019
HALBERSTADT ALCHATHA MKLEIN AKMCCORVY JDMEYER MRWAGMANN LSTRATFORD ABRANDT SD: "Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD", NEUROPHARMACOLOGY, vol. 172, 2020, pages 107856
LEA WAGMANN ET AL., ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2019
PAQUETTE, LEO A.: "Principles of Modern Heterocyclic Chemistry", 1968, W.A. BENJAMIN
"The Chemistry of Heterocyclic Compounds, A Series of Monographs", vol. 13,14,16,19,28, 1950, JOHN WILEY & SONS
J. AM. 15 CHEM. SOC., vol. 82, 1960, pages 5566
"Dictionary of Chemical Terms", 1984, MCGRAW-HILL
KOCIENSKI, PHILIP J.: "Stereochemistry of Organic Compounds", 1994, GEORG THIEME VERLAG STUTTGART
THEODORA W. GREENEPETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
WAGGER J ET AL.: "Synthesis of European pharmacopoeial impurities A, B, C, and D of cabergoline", RSC ADV., vol. 3, 2013, pages 23146 - 23156
INCZE M ET AL.: "Cyclopropanation of Carbon-Carbon Double Bonds in Ring D of Ergot Alkaloids", HETEROCYCLES, vol. 87, no. 7, 2013, pages 1553 - 1559
"Handbook of Pharmaceutical Excipients", 1986
WAGMANN ET AL.: "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures", ANAL BIOANAL CHEM, vol. 411, 2019, pages 4751 - 4763, XP036827220, DOI: 10.1007/s00216-018-1558-9
HALBERSTADT AL: "Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network", SCI REP, vol. 10, 2020, pages 8344
KARST M ET AL.: "The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series", CEPHALALGIA, vol. 30, no. 9, 2010, pages 1140 - 1144, XP009157353, DOI: 10.1177/0333102410363490
CLAIMS 1. A compound of formula (1) wherein X is selected from CO and SO2; Y is selected from a single chemical bond, O, S, and a C1–8 alkylene, C2–8 alkenylene, C2–4 alkynylene or O-C1–6 alkylene residue, wherein each of said alkylenes, alkenylenes or alkynylenes may be optionally substituted with C1–3 alkyl or halogen; Z is selected from hydrogen, halogen, cyano, C1–3 trialkylsilyl, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-12 alkoxy, C1-12 alkylthio, aryl, heterocyclyl, heteroaryl, metallocenyl, COOH, CO-C1-6 alkyl, CO-C3-7 cycloalkyl, O-CO-C1-6 alkyl, O-CO-C3-7 cycloalkyl, CO-C1-6 alkoxy or CO-C3-7 cycloalkoxy, wherein each of said alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkoxy, aryl, heterocyclyl, heteroaryl or metallocenyl may be optionally substituted with C1-5 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C1-3 haloalkyl, halogen, nitro, amino, hydroxy, oxo, COOH and CONH2; R2 is selected from hydrogen, C1-3 alkyl, C3-5 cycloalkyl, oxetane, C1-3 haloalkyl, C1- 3 alkylthio, halogen, cyano, COOH and CONH2; R6 is selected from C1-4 alkyl, C3-5 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, cyano and oxetane; Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-7 cycloalkyl, C2-4 haloalkyl, 2-methoxyethyl and 2-ethoxyethyl; or Ra and Rb, together with the adjacent nitrogen atom, form a 3 to 7 membered heterocyclic ring, wherein said heterocyclic ring may be optionally substituted with C1-3 alkyl or halogen; and is a single or double bond or a cyclopropyl ring; provided that compounds of formula (1) having a linear C1-5 acyl group, a valeroyl group or a cyclopropylcarbonyl group, as -XYZ are excluded;or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, wherein R2 is H, R6 is methyl, Ra = Rb = ethyl, is a double bond, X is C=O, Y is a bond or a C1–4 alkylene residue, which may be substituted with C1–3 alkyl or halogen, and Z is selected from hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-12 alkoxy, aryl, heterocyclyl, heteroaryl, COOH, and CO-C1-6 alkyl. 3. The compound of claim 2, wherein (i) Y is a chemical bond, and Z is furan-2-yl, furan-3-yl, tetrahydrofuran-2-yl, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl, oxetan-3-yl or oxan-4-yl; or (ii) Y is CH2CH2, and Z is COOCH3, phenyl, cyclohexyl or cyclopentyl; or (iii) Y is OCH(CH3), and Z is O-CO-CH(CH3)2; or (iv) Y is CH2CH2, and Z is hydrogen, phenyl or cyclopentyl. 4. The compound of any one of claims 1 to 3, which is selected from: 1-ethyl- carbamoyl-lysergic acid diethylamide (SYN-L-003), 1-dodecanoyl-lysergic acid diethylamide (SYN-L-004), 1-(2-furoyl)-lysergic acid diethylamide (SYN-L-005), 1-(3-phenylpropionoyl)-lysergic acid diethylamide (SYN-L-006), 1-(o-toluoyl)- lysergic acid diethylamide (SYN-L-008), 1-nicotinoyl-lysergic acid diethylamide (SYN-L-010), 1-methylsuccinyl-lysergic acid diethylamide (SYN-L-012), 1-ena- carbil-lysergic acid diethylamide (SYN-L-013), 1-cyclopropanesulfonyl-lysergic acid diethylamide (SYN-L-014), 1-methoxyacetyl-lysergic acid diethylamide (SYN-L-015), 1-propionyl-2-bromo-lysergic acid diethylamide (SYN-L-017), 1- benzoyl-lysergic acid diethylamide (SYN-L-018), 1-(2-thiophenecarbonyl)- lysergic acid diethylamide (SYN-L-021), 1-phenylacetyl-lysergic acid diethyl- amide (SYN-L-022), 1-(1-adamantanecarbonyl)-lysergic acid diethylamide (SYN- L-023), 1-pivaloyl-lysergic acid diethylamide (SYN-L-024), 1-isovaleryl-lysergic acid diethylamide (SYN-L-026), 1-hexanoyl-lysergic acid diethylamide (SYN-L- 027), 1-cyclopentanepropanoyl-lysergic acid diethylamide (SYN-L-028), 1-cyclo- hexanecarbonyl-lysergic acid diethylamide (SYN-L-029), 1-cyclopentanecarbonyl- lysergic acid diethylamide (SYN-L-030), 1-cyclobutanecarbonyl-lysergic acid diethylamide (SYN-L-031), 1-isobutyryl-lysergic acid diethylamide (SYN-L-032), 1-(5-methyl-2-furoyl)-lysergic acid diethylamide (SYN-L-034), 1-(5-tert-butyl-2- furoyl)-lysergic acid diethylamide (SYN-L-035), 1-(tetrahydro-2-furoyl)-lysergic acid diethylamide (SYN-L-036), 1-(3-furoyl)-lysergic acid diethylamide (SYN-L- 037), 1-(3-thiophenecarbonyl)-lysergic acid diethylamide (SYN-L-038), 1-iso- nicotinoyl-lysergic acid diethylamide (SYN-L-039), 1-(3-oxetanoyl)-lysergic acid diethylamide (SYN-L-040), 1-(4-tetrahydropyranoyl)-lysergic acid diethylamide (SYN-L-041), 1-(4-morpholinylbutyryl)-lysergic acid diethylamide (SYN-L-046), 1-(4-morpholinecarbonyl)-lysergic acid diethylamide (SYN-L-047), 1-(p-tosyl)- lysergic acid diethylamide (SYN-L-048), 1-(tert-butoxycarbonyl)-lysergic acid diethylamide (SYN-L-049), 1-(benzyloxycarbonyl)-lysergic acid diethylamide (SYN-L-050), 1-(bicyclo[1.1.1]pentylcarbonyl)-lysergic acid diethylamide (SYN-L- 051), 1-(tetramethylcyclopropylmethanoyl)-lysergic acid diethylamide (SYN-L- 052), 1-(2,3,3-trimethyl)butanoyl-lysergic acid diethylamide (SYN-L-053), 1-(4- tetrahydropyranacetyl)-lysergic acid diethylamide (SYN-L-056), 1-isopropoxy- acetate-lysergic acid diethylamide (SYN-L-060), 1-(3-ethoxypropanoyl)-lysergic acid diethylamide (SYN-L-061), 1-(3-phenylpropionyl)-2-bromo-lysergic acid diethylamide (SYN-L-079), 1-(pent-5-yn-1-oyl)-lysergic acid diethylamide (SYN- L-191), 1-(cyclopent-3-enecarbonyl)-lysergic acid diethylamide (SYN-L-192), 1- (3-thiomethylpropionyl)-lysergic acid diethylamide (SYN-L-193), 1-(cyclopent-2- eneacetyl)-lysergic acid diethylamide (SYN-L-194), 1-(2-benzothiophenecarbon- yl)-lysergic acid diethylamide (SYN-L-217), 1-spirobicyclobutanoyl-lysergic acid diethylamide (SYN-L-218), 1-trifluoroacetyl-lysergic acid diethylamide (SYN-L- 219), 1-(N-pyrrolidine)acetyl-lysergic acid diethylamide (SYN-L-220), 1-thieno- thiophenecarbonyl-lysergic acid diethylamide (SYN-L-221), 1-(3-tetrahydro- pyrancarbonyl)-lysergic acid diethylamide (SYN-L-223), 1-(3-butenoyl)-lysergic acid diethylamide (SYN-L-224), 1-(tetrahydro-2-thiophenecarbonyl)-lysergic acid diethylamide (SYN-L-225), 1-(tetrahydro-3-furoyl)-lysergic acid diethylamide (SYN-L-226), 1-(methylthio)acetyl-lysergic acid diethylamide (SYN-L-227), 1-(5- bromo-2-thiophenecarbonyl)-lysergic acid diethylamide (SYN-L-228), 1-(1,2-di- methylcyclobutane-1-carbonyl)-lysergic acid diethylamide (SYN-L-229), 1-(1,4- dimethylspiro[2.3]hexane-1-carbonyl)-lysergic acid diethylamide (SYN-L-230) and 1-(1,2-dimethylbicyclo[1.1.0]butane-2-carbonyl)-lysergic acid diethylamide (SYN-L-231), 1-(4-oxopentanoyl)-lysergic acid diethylamide (SYN-L-232), 1-(3- selenophenecarbonyl)-lysergic acid diethylamide (SYN-L-233), 1-(ferrocene- carbonyl)-lysergic acid diethylamide (SYN-L-234) and 1-(ferrocenecarbonyl)-6- allyl-6-nor-lysergic acid diethylamide (SYN-L-235), or a pharmaceutically acceptable salt thereof, preferably the compound is selected from SYN-L-005, SYN-L-012, SYN-L-013 and SYN-036, or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition comprising a compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 6. The pharmaceutical composition of claim 5, having modulated or reduced hallucinogenic side effects as compared to LSD and 1-acetyl-LSD. 7. A compound of formula (1) wherein X is selected from CO and SO2; Y is selected from a single chemical bond, O, S, and a C1–8 alkylene, C2–8 alkenylene, C2–4 alkynylene or O-C1–6 alkylene residue, wherein each of said alkylenes, alkenylenes or alkynylenes may be optionally substituted with C1–3 alkyl or halogen; Z is selected from hydrogen, halogen, cyano, C1–3 trialkylsilyl, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-12 alkoxy, C1-12 alkylthio, aryl, heterocyclyl, heteroaryl, metallocenyl, COOH, CO-C1-6 alkyl, CO-C3-7 cycloalkyl, O-CO-C1-6 alkyl, O-CO-C3-7 cycloalkyl, CO-C1-6 alkoxy or CO-C3-7 cycloalkoxy, wherein each of said alkyl, alkoxy, alkylthio cycloalkyl, cycloalkoxy, aryl, heterocyclyl, heteroaryl or metallocenyl may be optionally substituted with C1-5 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C1-3 haloalkyl, halogen, nitro, amino, hydroxy, oxo, COOH and CONH2; R2 is selected from hydrogen, C1-3 alkyl, C3-5 cycloalkyl, oxetane, C1-3 haloalkyl, C1- 3 alkylthio, halogen, cyano, COOH and CONH2; R6 is selected from C1-4 alkyl, C3-5 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, cyano and oxetane; Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-7 cycloalkyl, C2-4 haloalkyl, 2-methoxyethyl and 2-ethoxyethyl; or Ra and Rb together with the adjacent nitrogen atom form a 3 to 7 membered heterocyclic ring, wherein said heterocyclic ring may be optionally substituted with C1-3 alkyl or halogen; and is a single or double bond or a cyclopropyl ring; provided that if is a double bond, R2 is hydrogen, R6 is methyl, Ra and Rb are both ethyl, and X is CO, then Y-Z is not methyl, or a pharmaceutically acceptable salt thereof, for use in treating diseases, requiring modulated or reduced hallucinogenic side effects as compared to LSD and 1-acetyl-LSD, in a subject. 8. The compound for use in treating diseases requiring a modulated or reduced hallucinogenic side effects as compared to LSD and 1-acetyl-LSD of claim 7, wherein (i) R2 is H, R6 is methyl, Ra = Rb = ethyl, is a double bond, X is C=O, Y is a bond or a C1–4 alkylene residue, which may be substituted with C1–3 alkyl or halogen, and Z is selected from hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-12 alkoxy, aryl, heterocyclyl, heteroaryl, COOH, and CO-C1-6 alkyl; (ii) the compound is as defined in claim 3 or 4; (iii) the compound is selected from 1-acetyl-lysergic acid morpholide (SYN-L-196), 1-propionyl-6-methallyl-6-nor-lysergic acid diethylamide (SYN-L-203), 1- propionyl-6-allyl-6-nor-lysergic acid methylisopropylamide (SYN-L-073), 1- propionyl-2-bromo-lysergic acid diethylamide (SYN-L-017) and 1- cyclopropanesulfonyl-lysergic acid diethylamide (SYN-L-014); or (iv) compounds of formula (1) having a C2-5 acyl group as -XYZ, preferably including 1-propionoyl-lysergic acid diethylamide (1P-LSD), 1-butanoyl-lysergic acid diethylamide (1B-LSD), 1-cyclopropylcarbonyl-lysergic acid diethylamide (1cP-LSD), 1-valeroyl-lysergic acid diethylamide (1V-LSD), 1-propionoyl-6-allyl-6- nor-lysergic acid diethylamide (1P-AL-LAD), 1-cyclopropanecarbonyl-6-allyl-6- nor-lysergic acid diethylamide (1cP-AL-LAD), 1-propionoyl-6-ethyl-6-nor-lysergic acid diethylamide (1P-ETH-LAD), 1-propionyl-lysergic acid methylisopropylamide (1P-MIPLA) and 1-cyclopropanecarbonyl-lysergic acid methylisopropylamide (1cP- MIPLA). 9. The compound for use in treating diseases requiring a modulated or reduced hallucinogenic side effects as compared to LSD and 1-acetyl-LSD of claim 7 or 8, which (i) is for use in treating migraine headache in a subject; (ii) is for use in treating cluster headache in a subject; (iii) is for use in treating depression in a subject; (iv) is for use in treating anxiety in a subject; (v) is for use in treating post-traumatic stress disorder in a subject; (vi) is for use in treating glaucoma in a subject; or (vii) is for use in treating rheumatoid arthritis in a subject. 10. A method for treating diseases requiring a modulated or reduced hallucinogenic side effects as compared to LSD and 1-acetyl-LSD, said method comprising administering a compound of formula (1) wherein X is selected from CO and SO2; Y is selected from a single chemical bond, O, S, and a C1–8 alkylene, C2–8 alkenylene, C2–4 alkynylene or O-C1–6 alkylene residue, wherein each of said alkylenes, alkenylenes or alkynylenes may be optionally substituted with C1–3 alkyl or halogen; Z is selected from hydrogen, halogen, cyano, C1–3 trialkylsilyl, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-12 alkoxy, C1-12 alkylthio, aryl, heterocyclyl, heteroaryl, metallocenyl, COOH, CO-C1-6 alkyl, CO-C3-7 cycloalkyl, O-CO-C1-6 alkyl, O-CO-C3-7 cycloalkyl, CO-C1-6 alkoxy or CO-C3-7 cycloalkoxy, wherein each of said alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkoxy, aryl, heterocyclyl, heteroaryl or metallocenyl may be optionally substituted with C1-5 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C1-3 haloalkyl, halogen, nitro, amino, hydroxy, oxo, COOH and CONH2; R2 is selected from hydrogen, C1-3 alkyl, C3-5 cycloalkyl, oxetane, C1-3 haloalkyl, C1- 3 alkylthio, halogen, cyano, COOH and CONH2; R6 is selected from C1-4 alkyl, C3-5 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, cyano and oxetane; Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-7 cycloalkyl, C2-4 haloalkyl, 2-methoxyethyl and 2-ethoxyethyl; or Ra and Rb together with the adjacent nitrogen atom form a 3 to 7 membered heterocyclic ring, wherein said heterocyclic ring may be optionally substituted with C1-3 alkyl or halogen; and is a single or double bond or a cyclopropyl ring; provided that if is a double bond, R2 is hydrogen, R6 is methyl, Ra and Rb are both ethyl, and X is CO, then Y-Z is not methyl, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment. 11. The method of claim 10 which is (i) for treating migraine headache in a subject; (ii) for treating cluster headache in a subject; (iii) for treating depression in a subject; (iv) for treating anxiety in a subject; (v) for treating post-traumatic stress disorder in a subject; (vi) for treating glaucoma in a subject; or (vii) for treating rheumatoid arthritis in a subject. 12. A method for producing a compound of formula (1) wherein X is selected from CO and SO2; Y is selected from a single chemical bond, O, S, and a C1–8 alkylene, C2–8 alkenylene, C2–4 alkynylene or O-C1–6 alkylene residue, wherein each of said alkylenes, alkenylenes or alkynylenes may be optionally substituted with C1–3 alkyl or halogen; Z is selected from hydrogen, halogen, cyano, C1–3 trialkylsilyl, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-12 alkoxy, C1-12 alkylthio, aryl, heterocyclyl, heteroaryl, metallocenoyl, COOH, CO-C1-6 alkyl, CO-C3-7 cycloalkyl, O-CO-C1-6 alkyl, O-CO-C3-7 cycloalkyl, CO-C1-6 alkoxy or CO-C3-7 cycloalkoxy, wherein each of said alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkoxy, aryl, heterocyclyl, heteroaryl or metallocenoyl may be optionally substituted with C1-5 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C1-3 haloalkyl, halogen, nitro, amino, hydroxy, oxo, COOH and CONH2; or -XYZ together represent hydrogen; R2 is Br; R6 is selected from C1-4 alkyl, C3-5 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, cyano and oxetane; Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-7 cycloalkyl, C2-4 haloalkyl, 2-methoxyethyl and 2-ethoxyethyl; or Ra and Rb together with the adjacent nitrogen atom form a 3 to 7 membered heterocyclic ring, wherein said heterocyclic ring may be optionally substituted with C1-3 alkyl or halogen; and is a single or double bond or a cyclopropyl ring, or a salt thereof, said method comprises saponifying bromocriptine followed by amide-formation as shown in the following reaction scheme: wherein the variables are as defined above. 13. The method of claim 12, wherein (a) the saponification comprises reaction in an aqueous medium with a base in the presence of sodium dithionite and a phase transfer catalyst; and/or (b) the amide-formation comprises reaction of the compound of formula (3) with HNRaRb in the presence of a carboxylic acid activating agent, preferably in the presence of POCl3. 14. The method of claim 12 or 13, which further comprises (c) for preparing a compound of formula (1) where R6 is not methyl, exchanging/extending the residue R6 in the compound of formula (3) or (4); and/or (d) for preparing a compound of formula (1) where -XYZ is not hydrogen, acylating or sulfonylating the compound of formula (4). 15. A compound of the formula (4) wherein Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-7 cycloalkyl, C2-4 haloalkyl, 2-methoxyethyl and 2- ethoxyethyl; or Ra and Rb together with the adjacent nitrogen atom form a 3 to 7 membered heterocyclyl ring, wherein said heterocyclyl ring may be optionally substituted with C1-3 alkyl or halogen, or a salt thereof. |
Scheme 5 The compound of formula A13 can be obtained from standard commercial suppliers or synthesised as needed by methods already described in the literature and known to those skilled in the art. The compound of formula A11 is known as bromocriptine, an important ergoline dopamine agonist used in the treatment of Parkinson’s disease and several other diseases. As such, bromocriptine is a widely distributed medication and available cheaply and easily from commercial suppliers without the need for any controlled substance licences. An important feature of this invention, as described by General Method E and Scheme 5, is the use of bromocriptine or it’s salts to access several compounds of formula (1) as well as intermediates and compounds including, but not limited to those described by formulas A12, A14 and A15. The use of bromocriptine to access these molecules provides a cost-effective, robust and flexible method of synthesis with a good yield. In the first step, PTC, base and sodium dithionite are dissolved in water at room temperature under a nitrogen atmosphere. With stirring, compound of formula A11 is added in small portions forming a mixture. The reaction is heated to reflux for 2 to 12 h before cooling to room temperature. The resulting dark solution is acidified with acetic acid until a pH of 6 to 6.5 is maintained. With continued stirring, the reaction is cooled to 0 °C to 5 °C for 2 to 12 h, effectuating precipitation. The mixture is filtered under vacuum and the filter cake washed with several portions of water and then isopropanol. The filter cake is dried in the oven at 50 °C to 100 °C for 1 to 4 days under hard vacuum. The resulting solid, compound of formula A12, is either used directly in the next step or purified by processes known to the art such as flash column chromatography, crystallisation or preparative HPLC. In the second step, compound of formula A12 is suspended in chloroform at room temperature under a nitrogen atmosphere. With stirring, a compound of formula A13 is added in one portion. The reaction is heated to 20 °C to 50 °C and phosphorus oxychloride is added in a dropwise manner such that reflux is maintained. After the addition, the reaction is stirred for an additional 20 min to 120 min. With continued stirring, water and then concentrated aqueous ammonia is added such that the mixture is sufficiently basic. The layers are allowed to separate and the aqueous phase is extracted with dichloromethane. The combined organics are washed with water and brine and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue, compound of formular A14, is purified by processes known to the art such as flash column chromatography, crystallisation or preparative HPLC. The general method E is further explained in Examples 10 and 11 below To access further R 2 substituted derivatives, as described in formula (1), where R 2 is as defined for the invention, further transformations can be made using compounds of formula A14 via methods described in the literature and known to those skilled in the art. These compounds can then be further functionalised as per Schemes 1, 2, 3, 4, 6 and 7, as appropriate. IV. F. General Methods - Transformations for Lysergamides Compounds of formula (1) can be prepared using the synthetic route detailed in Scheme 6, in which, R a , R b , R 2 , R 6 , X, Y and Z are as defined for the invention and is a single bond. The last step in the procedure, to obtain compounds of formula A17, can employ either that described in Scheme 1, that described in Scheme 2 or that described in Scheme 3. Scheme 6 To access compounds of formula A17, further transformations can be made using compounds of formula A9 by employing the same hydrogenation strategy as described by Wagger et al.( Wagger J, et al. Synthesis of European pharmacopoeial impurities A, B, C, and D of cabergoline. RSC Adv., 2013, 3, 23146-23156. DOI: 10.1039/C3RA43417F ) or via other methods described in the literature and known to those skilled in the art. Such General Method F is further explained in Example 12 below. These compounds can then be further functionalised as per Schemes 1, 2 and 3, as appropriate. Furthermore, compounds of formula (1) can be prepared using the synthetic route detailed in Scheme 7, in which, R a , R b , R 2 , R 6 , X, Y and Z are as defined for the invention and is a cyclopropyl group. The last step in the procedure, to obtain compounds of formula A19, can employ either that described in Scheme 1, that described in Scheme 2 or that described in Scheme 3. Scheme 7 To access compounds of formula A19, further transformations can be made using compounds of formula A9 by employing the same cyclopropanation strategy as described by Incze et al. (Incze M, et al. Cyclopropanation of Carbon-Carbon Double Bonds in Ring D of Ergot Alkaloids. Heterocycles 2013; 87( 7): 1553 – 1559. DOI: 10.3987/COM-13-12735) or via other methods described in the literature and known to those skilled in the art. Such General Method F is further explained in Example 13 below. These compounds can then be further functionalised as per Schemes 1, 2 and 3, as appropriate. V. Pharmaceutical Compositions The compounds of formula (1) utilized in the pharmaceutical composition of the second aspect of the invention and the compounds/medicaments for use in treating diseases of the third aspect of the invention (hereinafter shortly referred to as “pharmaceutical composition of the invention” and “medicament of the invention”) and the medical treatment of the fourth aspect of the invention can be used in a range of medicinal applications as described hereinbefore. While it is possible for the active ingredients to be administered alone (which is also contemplated as a separate aspect of the invention), it may be preferable to present them as pharmaceutical compositions. The pharmaceutical compositions and medicaments of the invention comprise one or more compounds of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients. The carriers must be “acceptable” in the sense of being compatible with the other ingredients of the composition and physiologically innocuous to the recipient. The carrier must also be suitable for the mode of administration of the active agent. In the second aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier. Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, gel, caps, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents including sweetening agents, flavouring agents, colouring agents and preserving agents, in order to provide a palatable preparation. Compositions intended for buccal or sublingual use may include orally disintegrating tablets or wafers which may be prepared by methods known to those skilled in the art. Compositions intended for intranasal use may include nasal sprays or nebuliser formulations which may be prepared by methods known to those skilled in the art. Compounds intended for injection may include aqueous formulations for intravenous use and lipophilic formulations for intramuscular depot injection, which may be prepared by methods known to those skilled in the art. The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain carriers, excipients, glidants, fillers, binders and the like. Aqueous compositions are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All compositions will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety. Carriers and excipients include methylsulfonylmethane (MSM), 2-hydroxypropyl beta- cyclodextrin, mannitol, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the compositions ranges from about 3 to about 11 but is ordinarily about 7 to 10. The pharmaceutical composition and medicaments of the invention may exist in a suspension. Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more colouring agents, one or more flavouring agents and one or more sweetening agents, such as sucrose or saccharin. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present. Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth herein, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid. The pharmaceutical compositions and medicaments of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent. The oily phase of the emulsions may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of cream compositions. Emulgents and emulsion stabilisers suitable for use in the composition and medicaments of the invention include Tween ® 20 or 60, Span ® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate. The invention is furthermore described in the following Examples, which shall, however, not be construed as limiting the present invention. The aspects and embodiments of the invention described above and described in the following examples are intended to be merely exemplary, and those skilled in the art will recognise, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific materials, compounds, and procedures. All such equivalents are considered to be within the scope of the invention as set out in the accompanying claims. Examples Example 1 – SYN-L-027 (1-hexanoyl-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in dichloromethane (30 ml) at room temperature and under a nitrogen atmosphere. With vigorous stirring, tetrabutylammonium hydrogensulfate (316 mg, 0.930 mmol, 0.6 eq) and powdered dry sodium hydroxide (3100 mg, 77.5 mmol, 50 eq) was added forming a biphasic mixture. The reaction was cooled to -10 °C and hexanoyl chloride (626 mg, 4.65 mmol, 3 eq) was added in a dropwise manner such that the reaction temperature did not exceed -5 °C. After stirring at -10 °C for 3 h, the reaction mixture was filtered over celite and extracted with a dichloromethane (2 x 20 ml). The organic phase was washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue, was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 415 mg (65 %) of SYN-L-027 as a brown oil. Example 2 – SYN-L-008 (1-(o-toluoyl)-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in dichloromethane (30 ml) at room temperature and under a nitrogen atmosphere. With vigorous stirring, tetrabutylammonium hydrogensulfate (316 mg, 0.930 mmol, 0.6 eq) and powdered dry sodium hydroxide (3100 mg, 77.5 mmol, 50 eq) was added forming a biphasic mixture. The reaction was cooled to -10 °C and o- toluoyl chloride (719 mg, 4.65 mmol, 3 eq) was added in a dropwise manner such that the reaction temperature did not exceed -5 °C. After stirring at -5 °C for 1 h, the reaction mixture was filtered over celite and extracted with a dichloromethane (2 x 20 ml). The organic phase was washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting product was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 561 mg (82 %) of SYN-L-008 as a brown oil. Example 3 – SYN-L-014 (1-cyclopropanesulfonyl-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (20 ml) and cooled to -78 °C under a nitrogen atmosphere. With stirring, n-butyllithium (1.94 ml of 1.6 M in hexane, 3.10 mmol, 2 eq) was added in a dropwise manner such that the reaction temperature did not exceed -70 °C. After stirring for 45 min, cyclopropylsulfonyl chloride (436 mg, 3.10 mmol, 2 eq) was then added in a dropwise manner such that the reaction temperature did not exceed -70 °C. The resulting mixture was stirred at -78 °C overnight before careful addition of water (15 ml). The aqueous phase was extracted with dichloromethane (3 x 30 ml) and the organic phase washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 79 mg (12 %) of SYN-L-014 as a brown solid. Example 4 – SYN-L-015 (1-methoxyacetyl-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (20 ml) and cooled to -78 °C under a nitrogen atmosphere. With stirring, n-butyllithium (1.94 ml of 1.6 M in hexane, 3.10 mmol, 2 eq) was added in a dropwise manner such that the reaction temperature did not exceed -70 °C. After stirring for 60 min, methoxyacetyl chloride (336 mg, 3.10 mmol, 2 eq) was then added in a dropwise manner such that the reaction temperature did not exceed -70 °C. The resulting mixture was stirred at -78 °C overnight before careful addition of water (15 ml). The aqueous phase was extracted with dichloromethane (3 x 30 ml) and the organic phase washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 49 mg (8 %) of SYN-L-015 as a brown oil. Example 5 – SYN-L-013 (1-enacarbil-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (20 ml) and cooled to -78 °C under a nitrogen atmosphere. With stirring, n-butyllithium (1.94 ml of 1.6 M in hexane, 3.10 mmol, 2 eq) was added in a dropwise manner such that the reaction temperature did not exceed -70 °C. After stirring for 30 min, 1-chloroethyl chloroformate (443 mg, 3.10 mmol, 2 eq) was then added in a dropwise manner such that the reaction temperature did not exceed -70 °C. The resulting mixture was stirred at -78 °C overnight before careful addition of water (15 ml). The aqueous phase was extracted with dichloromethane (3 x 30 ml) and the organic phase washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue was then dissolved in N,N-dimethylformamide (5 ml). This was then added to a flask containing cesium isobutyrate (1360 mg, 6.20 mmol, 4 eq) dissolved in N,N-dimethylformamide (5 ml) under a nitrogen atmosphere and with stirring. After heating for 1 hr at 60 °C, the orange solution was allowed to cool to room temperature before diluting with ethyl acetate (40 ml). The organic phase was washed with saturated aqueous ammonium chloride solution (3 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue was then purified by silica gel flash column chromatography using a toluene/acetone gradient. There was obtained 67 mg (9 %) of SYN-L-013 as a brown oil. Example 6 – SYN-L-012 (1-(methylsuccinyl)-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in anhydrous acetonitrile (30 ml) at room temperature and under a nitrogen atmosphere. With stirring, succinylimidazole-monomethyl ester (339 mg, 1.86 mmol, 1.2 eq) and DBU (118 mg, 0.775 mmol, 0.5 eq) was added forming a dark solution. The reaction was heated at 40 °C for 1 h and then concentrated under vacuum. The residue was dissolved in dichloromethane (90 ml), washed with saturated sodium bicarbonate solution (1 x 15 ml), water (1 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 529 mg (78 %) of SYN-L-012 as a brown foam. Example 7 – SYN-L-068 (1-(2-furoyl)-lysergic acid 2,4-dimethylazetidide) d-lysergic acid-2,4-dimethylazetidine (500 mg, 1.49 mmol, 1 eq) was dissolved in anhydrous acetonitrile (30 ml) at room temperature and under a nitrogen atmosphere. With stirring, 1-(2-furoyl)-imidazole (266 mg, 1.64 mmol, 1.1 eq) and DBU (113 mg, 0.745 mmol, 0.5 eq) was added forming a dark solution. The reaction was heated at 50 °C for 3 h and then concentrated under vacuum. The residue was dissolved in dichloromethane (90 ml), washed with saturated sodium bicarbonate solution (1 x 15 ml), water (1 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 454 mg (73 %) of SYN- L-068 as a brown foam. Example 8 – SYN-L-205 (1-(2-thiophenecarbonyl)-6-ethyl-6-nor-lysergic acid methylisopropylamide) Step 1: 1-propionyl-lysergic acid methylisopropylamide (500 mg, 1.32 mmol, 1 eq) was dissolved in chloroform (40 ml) at room temperature and under a nitrogen atmosphere. With stirring, cyanogen bromide (560 mg, 5.28 mmol, 4 eq) was carefully added forming a dark mixture. The reaction was heated at reflux for 8 h before cooling to room temperature and filtering over celite. The celite was extracted with further portions of chloroform (2 x 20 ml) and the combined organics were concentrated under vacuum to dryness. There was obtained 1- propionyl-6-cyano-6-nor-lysergic acid methylisopropylamide as a crude solid, which was used directly in the next step. Step 2: The entire crude mass of 1-propionyl-6-cyano-6-nor-lysergic acid methylisopropylamide from step 1 was dissolved in glacial acetic acid (10 ml) at room temperature under a nitrogen atmosphere. With stirring, water (2 ml) and finely powder zinc (860 mg) was carefully added forming a suspension. The reaction was heated at reflux for 4 h before cooling to room temperature. With continued stirring, the reaction mixture was diluted with water (10 ml) and chilled before a portion of dichloromethane (30 ml) was added. Concentrated aqueous ammonia was added in a dropwise manner until a pH of 9 to 10 was maintained. The phases were allowed to separate and the aqueous layer was extracted with further portions of dichloromethane (2 x 20 ml). The combined organics were washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. There was obtained 1- propionyl-6-nor-lysergic acid methylisopropylamide as a crude residue, which was used directly in the next step. Step 3: The entire crude mass of 1-propionyl-6-nor-lysergic acid methylisopropylamide from step 2 was dissolved in anhydrous acetonitrile (30 ml) at room temperature under a nitrogen atmosphere. Anhydrous potassium carbonate (900 mg) and ethyl iodide (220 mg) was added forming a suspension. This was heated at 50 °C for 3 h before concentrating under hard vacuum. The residue was taken up in dichloromethane (50 ml), filtered over celite and the organics dried over magnesium sulphate before concentrating under vacuum. The resulting residue, was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 156 mg (30 % over 3 steps) of 1-propionyl-6-ethyl-6-nor-lysergic acid methylisopropylamide as a brown foam. Step 4: 1-propionyl-6-ethyl-6-nor-lysergic acid methylisopropylamide (150 mg, 0.381 mmol, 1 eq) was dissolved in methanol (20 ml) at room temperature under a nitrogen atmosphere. With stirring, concentrated aqueous ammonia (10 ml) was added and the homogenous mixture heated at 35 °C for 12 h. After cooling to room temperature, the methanol was removed under vacuum effectuating the precipitation of a gummy residue. The mixture was taken up in dichloromethane (30 ml) and the phases allowed to separate. The aqueous phase is extracted with further portions of dichloromethane (2 x 10 ml) and the combined organics are dried over magnesium sulphate before concentrating under vacuum. The resulting residue, was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 105 mg (82 %) of 6- ethyl-6-nor-lysergic acid methylisopropylamide as a beige foam. This was then acylated with 1-(2-thiophenecarbonyl)-imidazole using General Method C, as described by Scheme 3 to obtain 100 mg (72 %) of SYN-L-205 as a brown solid. Example 9 – SYN-L-143 (1-(2-furoyl)-6-allyl-6-nor-lysergic acid diethylamide) Step 1: 1-propionyl-lysergic acid lysergic acid diethylamide (500 mg, 1.32 mmol, 1 eq) was dissolved in chloroform (40 ml) at room temperature and under a nitrogen atmosphere. With stirring, cyanogen bromide (560 mg, 5.28 mmol, 4 eq) was carefully added forming a dark mixture. The reaction was heated at reflux for 6 h before cooling to room temperature and filtering over celite. The celite was extracted with further portions of chloroform (2 x 20 ml) and the combined organics were concentrated under vacuum to dryness. There was obtained 1- propionyl-6-cyano-6-nor-lysergic acid diethylamide as a crude solid, which was used directly in the next step. Step 2: The entire crude mass of 1-propionyl-6-cyano-6-nor-lysergic acid diethylamide from step 1 was dissolved in glacial acetic acid (10 ml) at room temperature under a nitrogen atmosphere. With stirring, water (2 ml) and finely powder zinc (860 mg) was carefully added forming a suspension. The reaction was heated at reflux for 5 h before cooling to room temperature. With continued stirring, the reaction mixture was diluted with water (10 ml) and chilled before a portion of dichloromethane (30 ml) was added. Concentrated aqueous ammonia was added in a dropwise manner until a pH of 9 to 10 was maintained. The phases were allowed to separate and the aqueous layer was extracted with further portions of dichloromethane (2 x 20 ml). The combined organics were washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. There was obtained 1-propionyl-6-nor- lysergic acid diethylamide as a crude residue, which was used directly in the next step. Step 3: The entire crude mass of 1-propionyl-6-nor-lysergic acid diethylamide from step 2 was dissolved in anhydrous acetonitrile (30 ml) at room temperature under a nitrogen atmosphere. Anhydrous potassium carbonate (900 mg) and allyl bromide (160 mg) was added forming a suspension. This was heated at 40 °C for 6 h before concentrating under hard vacuum. The residue was taken up in dichloromethane (50 ml), filtered over celite and the organics dried over magnesium sulphate before concentrating under vacuum. The resulting residue, was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 203 mg (38 % over 3 steps) of 1-propionyl-6-allyl-6-nor-lysergic acid diethylamide as a brown foam. Step 4: 1-propionyl-6-allyl-6-nor-lysergic acid diethylamide (150 mg, 0.370 mmol, 1 eq) was dissolved in methanol (20 ml) at room temperature under a nitrogen atmosphere. With stirring, concentrated aqueous ammonia (10 ml) was added and the homogenous mixture heated at 45 °C for 8 h. After cooling to room temperature, the methanol was removed under vacuum effectuating the precipitation of a gummy residue. The mixture was taken up in dichloromethane (30 ml) and the phases allowed to separate. The aqueous phase is extracted with further portions of dichloromethane (2 x 10 ml) and the combined organics are dried over magnesium sulphate before concentrating under vacuum. The resulting residue, was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 110 mg (85 %) of 6-allyl- 6-nor-lysergic acid diethylamide as a beige foam. This was then acylated with 1- (2-furoyl)-imidazole using General Method C, as described by Scheme 3 to obtain 95 mg (68 %) of SYN-L-143 as a brown solid. Example 10 – SYN-L-017 (1-propionyl-2-bromo-lysergic acid diethylamide) Step 1: Tetrabutylammonium hydroxide aqueous solution (13.8 g, 53.2 mmol, 4 eq), sodium hydroxide (3.19g, 79.8 mmol, 6 eq), sodium dithionite (0.463 g, 2.66 mmol, 0.2 eq) were dissolved in water (80 ml) at room temperature under a nitrogen atmosphere. With stirring, bromocriptine mesylate (10.0 g, 13.3 mmol, 1 eq) was added in small portions forming a mixture. The reaction was heated to reflux for 8 h before cooling to room temperature. The resulting dark solution was acidified with acetic acid until a pH of 6 to 6.5 was maintained. With continued stirring, the reaction was cooled to 5 °C for 8 h, effectuating precipitation. The mixture was filtered under vacuum and the filter cake washed with several portions of water (3 x 60 ml) and then isopropanol (1 x 60 ml). The filter cake was dried in the oven at 80 C for 3 days under hard vacuum. There was obtained 3.00 g (65 %) of 2-bromo-lysergic acid as a grey solid, which didn’t require additional purification and was used directly in the next step. Step 2: 2-bromo-lysergic acid (1.00 g, 2.88 mmol, 1 eq) was suspended in chloroform (25 ml) at room temperature under a nitrogen atmosphere. With stirring, diethylamine (1.90 g, 25.9 mmol, 9 eq) was added in one portion. The reaction was heated to 40 C and phosphorus oxychloride (0.883 g, 5.76 mmol, 2 eq) was added in a dropwise manner such that reflux was maintained. After the addition, the reaction was stirred for an additional 30 min. With continued stirring, water (10 ml) and then concentrated aqueous ammonia was added such that the mixture was sufficiently basic. The layers were allowed to separate and the aqueous phase was extracted with dichloromethane (2 x 30 ml). The combined organics were washed with water (2 x 15 ml) and brine (1 x 15 ml) and then dried over magnesium sulphate before concentrating under vacuum. The resulting residue, was then purified by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 658 mg (57 %) of 2- bromo-lysergic acid diethylamide as a light brown foam. This was then acylated with propionyl chloride using General Method A, as described by Scheme 1 to obtain 448 mg (60 %) of SYN-L-017 as a brown oil. Example 11 – SYN-L-206 (1-propionyl-2-methyl-lysergic acid diethylamide) 2-bromo-lysergic acid diethylamide (200 mg, 0.499 mmol, 1 eq) and [1,1′- Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (18.3 mg, 0.0250 mmol, 0.05 eq) was dissolved in anhydrous 1,4-dioxane (8 ml) at room temperature under a nitrogen atmosphere. Dimethyl zinc solution (95.3 mg, 0.998 mmol, 2 eq) was carefully added and the reaction heated to reflux for 90 min. After cooling to room temperature, the reaction was quenched with methanol (8 ml) and concentrated under vacuum. The resulting residue, was then purified directly by silica gel flash column chromatography using an ethyl acetate/isopropanol gradient. There was obtained 71 mg (42 %) of 2-methyl-lysergic acid diethylamide as a brown oil. This was then acylated with propionyl chloride using General Method A, as described by Scheme 1 to obtain 56 mg (68 %) of SYN-L-206 as a brown oil. Example 12 – SYN-L-212 (1-propionyl-9,10-dihydro-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) was dissolved in anhydrous methanol (20 ml) at 35 °C. With stirring, palladium (125 mg, 10% on carbon) suspended in methanol (5 ml) was added and the reaction mixture was purged with nitrogen. The reaction was then purged with hydrogen and put under a hydrogen balloon at 35 °C for 5 h. After cooling to room temperature, the reaction mixture was filter over celite and extracted with methanol (2 x 20 ml). The combined organics were concentrated under vacuum and the resulting residue was purified directly by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 408 mg (81 %) of 9,10- dihydro-lysergic acid diethylamide as a light foam. This was then acylated with 1- propionylimidazole using General Method C, as described by Scheme 3 to obtain 363 mg (76 %) of SYN-L-212 as a light brown oil. Example 13 – SYN-L-211 (1-propionyl-9,10-cyclopropyl-lysergic acid diethylamide) d-lysergic acid diethylamide (500 mg, 1.55 mmol, 1 eq) and palladium(II) acetate (69.6 mg, 0.310 mmol, 0.2 eq) was dissolved in dichloromethane (20 ml) at room temperature under a nitrogen atmosphere. With stirring and cooling to 0 °C, diazomethane solution (1.30 g, 31.0 mmol, 20 eq) was added slowly in a dropwise manner. Stirring was continued at 0 °C for 6 h before filtering and concentrating the organics under vacuum. The resulting residue was purified directly by silica gel flash column chromatography using a dichloromethane/methanol gradient. There was obtained 94 mg (18 %) of 9,10-cyclopropyl-lysergic acid diethylamide as a brown oil. This was then acylated with 1-propionylimidazole using General Method C, as described by Scheme 3 to obtain 78 mg (71 %) of SYN-L-211 as a brown oil. Further compounds of the invention were prepared following the teaching of the Ggeneral methods and specific preparation examples, as reflected in the following analytical characterization and pharmaceutical testing, as a person skilled in the art would know how to modify the General Methods to accommodate the different substituents that may be present on the compounds of the invention. Analytical characterisation, Compounds of the invention, Characterisation data: 1 H NMR for selected compounds SYN-L-004 to SYN-L-236 of the invention are shown in the following. SYN-L-003, 1-ethylcarbamoyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.30 (3H, t), 2.57 (3H, s), 2.83-3.06 (4H, m), 3.22-3.40 (5H, m), 4.03 (1H, dd), 4.13-4.25 (2H, m), 6.16 (1H, d), 6.91-7.17 (2H, m), 7.65 (1H, ddd), 7.73 (1H, d). SYN-L-004, 1-dodecanoyl-lysergic acid diethylamide: 1H NMR: δ 0.86 (3H, t), 1.16-1.34 (22H, m), 1.47-1.59 (2H, m), 2.52-2.68 (5H, m), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.95 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.53 (1H, ddd), 7.93 (1H, d). SYN-L-005, 1-(2-furoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.83-3.06 (4H, m), 3.22-3.41 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.65 (1H, dd), 6.88-7.13 (2H, m), 7.30 (1H, dd), 7.56 (1H, m), 7.84 (1H, dd), 8.00 (1H, d). SYN-L-006, 1-(3-phenylpropanoyl)-lysergic acid diethylamide : 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.73-3.08 (8H, m), 3.22-3.41 (5H, m), 3.95 (1H, dd), 6.15 (1H, d), 6.87-7.34 (7H, m), 7.53 (1H, m), 7.93 (1H, d). SYN-L-008, 1-(o-toluoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.40 (3H, s), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.87-7.23 (3H, m), 7.38-7.72 (4H, m), 7.97 (1H, d). SYN-L-010, 1-nicotinoyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.99 (1H, dd), 6.15 (1H, d), 6.88-7.13 (2H, m), 7.47-7.61 (2H, m), 7.94 (1H, d), 8.07 (1H, ddd), 8.63 (1H, dt), 9.08 (1H, ddd). SYN-L-011, 1-succinyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.79-3.07 (8H, m), 3.22-3.41 (5H, m), 3.99 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.53 (1H, ddd), 7.93 (1H, d). SYN-L-012, 1-methylsuccinyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.69-2.81 (2H, m), 2.82-3.07 (6H, m), 3.22- 3.41 (5H, m), 3.64 (3H, s), 3.99 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.53 (1H, ddd), 7.93 (1H, d). SYN-L-013, 1-enacarbil-lysergic acid diethylamide: 1H NMR: δ 1.06-1.28 (12H, m), 1.61 (3H, d), 2.42 (1H, m), 2.57 (3H, s), 2.82- 3.06 (4H, m), 3.22-3.42 (5H, m), 3.98 (1H, dd), 6.01-6.21 (2H, m), 6.91-7.18 (2H, m), 7.65 (1H, ddd), 7.75 (1H, d). SYN-L-014, 1-cyclopropanesulfonyl-lysergic acid diethylamide: 1H NMR: δ 1.16-1.39 (10H, m), 2.57 (3H, s), 2.92-3.17 (4H, m), 3.18-3.40 (6H, m), 4.40 (1H, dd), 6.19 (1H, d), 7.11-7.46 (3H, m), 8.30 (1H, d). SYN-L-015, 1-methoxyacetyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.16-3.41 (8H, m), 3.99 (1H, dd), 4.47-4.57 (2H, m), 6.15 (1H, d), 6.88-7.13 (2H, m), 7.55 (1H, ddd), 8.01 (1H, d). SYN-L-017, 1-propionyl-2-bromo-lysergic acid diethylamide: 1H NMR: δ 1.06 (3H, t), 1.22 (6H, t), 2.57 (3H, s), 2.63-2.75 (2H, m), 2.92-3.12 (4H, m), 3.22-3.38 (5H, m), 4.03 (1H, dd), 6.13 (1H, d), 6.87-7.09 (2H, m), 7.27 (1H, dd). SYN-L-018, 1-benzoyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.99 (1H, dd), 6.15 (1H, d), 6.87-7.13 (2H, m), 7.39-7.75 (6H, m), 7.93 (1H, d). SYN-L-021, 1-(2-thiophenecarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.88-7.13 (2H, m), 7.20 (1H, dd), 7.59 (1H, ddd), 7.77 (1H, dd), 7.96 (1H, dd), 7.98 (1H, d). SYN-L-022, 1-phenylacetyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.88- 4.12 (3H, m), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.21-7.45 (5H, m), 7.54 (1H, ddd), 7.98 (1H, d). SYN-L-023, 1-(1-adamantanecarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.58-1.73 (6H, m), 1.77-1.94 (9H, m), 2.57 (3H, s), 2.81- 3.07 (4H, m), 3.22-3.40 (5H, m), 3.99 (1H, dd), 6.16 (1H, d), 6.88-7.13 (2H, m), 7.53 (1H, ddd), 8.00 (1H, d). SYN-L-024, 1-pivaloyl-lysergic acid diethylamide: 1H NMR: δ 1.16-1.28 (15H, m), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.95 (1H, dd), 6.15 (1H, d), 6.88-7.13 (2H, m), 7.54 (1H, ddd), 7.98 (1H, d). SYN-L-026, 1-isovaleryl-lysergic acid diethylamide: 1H NMR: δ 0.81-0.93 (6H, m), 1.22 (6H, t), 1.92 (1H, m), 2.50-2.62 (5H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-027, 1-hexanoyl-lysergic acid diethylamide: 1H NMR: δ 0.87 (3H, t), 1.16-1.35 (10H, m), 1.46-1.58 (2H, m), 2.52-2.68 (5H, m), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.99 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.53 (1H, ddd), 7.93 (1H, d). SYN-L-028, 1-cyclopentanepropanoyl-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 1.35-1.78 (10H,), 1.96 (1H, m), 2.52-2.70 (5H, m), 2.81- 3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-029, 1-cyclohexanecarbonyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.29-1.70 (6H, m), 1.76-2.06 (4H, m), 2.57 (3H, s), 2.81- 3.06 (4H, m), 3.22-3.40 (6H, m), 4.00 (1H, dd), 6.16 (1H, d), 6.87-7.13 (2H, m), 7.53 (1H, ddd), 7.98 (1H, d). SYN-L-030, 1-cyclopentanecarbonyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.60-2.18 (8H, m), 2.57 (3H, s), 2.81-3.06 (4H, m), 3.22- 3.50 (6H, m), 4.00 (1H, dd), 6.16 (1H, d), 6.87-7.12 (2H, m), 7.52 (1H, ddd), 7.98 (1H, d). SYN-L-031, 1-cyclobutanecarbonyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.80-2.03 (2H, m), 2.21-2.47 (4H, m), 2.57 (3H, s), 2.82- 3.07 (4H, m), 3.18-3.43 (6H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.97 (1H, d). SYN-L-032, 1-isobutyryl-lysergic acid diethylamide: 1H NMR: δ 1.07-1.28 (12H, m), 2.57 (3H, s), 2.75-3.07 (5H, m), 3.22-3.43 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.97 (1H, d). SYN-L-033, 1-(4-methylpentanoyl)-lysergic acid diethylamide: 1H NMR: δ 0.83-0.94 (6H, m), 1.22 (6H, t), 1.36-1.55 (3H, m), 2.52-2.69 (5H, m), 2.82-3.07 (4H, m), 3.22-3.43 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.85-7.12 (2H, m), 7.23 (1H, ddd), 7.97 (1H, d). SYN-L-034, 1-(5-methyl-2-furoyl)-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 2.42-2.62 (6H, m), 2.82-3.07 (4H, m), 3.22-3.40 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.34 (1H, d), 6.88-7.13 (2H, m), 7.20 (1H, d), 7.54 (1H, ddd), 8.00 (1H, d). SYN-L-035, 1-(5-tert-butyl-2-furoyl)-lysergic acid diethylamide: 1H NMR: δ 1.16-1.29 (15H, m), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.40 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.45 (1H, d), 6.88-7.13 (2H, m), 7.23 (1H, d), 7.54 (1H, ddd), 8.00 (1H, d). SYN-L-036, 1-(tetrahydro-2-furoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.96-2.20 (4H, m), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22- 3.41 (5H, m), 3.61-3.79 (2H, m), 3.95 (1H, dd), 5.25 (1H, dd), 6.15 (1H, d), 6.88- 7.13 (2H, m), 7.55 (1H, ddd), 8.03 (1H, d). SYN-L-037, 1-(3-furoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.40 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.84-7.13 (3H, m), 7.47-7.74 (3H, m), 7.89 (1H, d). SYN-L-038, 1-(3-thiophenecarbonyl)-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.40 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.88-7.13 (2H, m), 7.54 (1H, ddd), 7.62-7.80 (2H, m), 7.97 (1H, d), 8.32 (1H, dd). SYN-L-039, 1-isonicotinoyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.41 (5H, m), 4.01 (1H, dd), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.26 (1H, ddd), 7.87-8.04 (3H, m), 8.71 (2H, ddd). SYN-L-040, 1-(3-oxetanoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.49 (6H, m), 3.88- 4.09 (5H, m), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.99 (1H, d). SYN-L-041, 1-(4-tetrahydropyrancarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.75-1.92 (4H, m), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22- 3.64 (10H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.98 (1H, d). SYN-L-042, 1-stearoyl-lysergic acid diethylamide: 1H NMR: δ 0.86 (3H, t), 1.16-1.34 (34H, m), 1.47-1.59 (2H, m), 2.52-2.68 (5H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-043, 1-oleoyl-lysergic acid diethylamide: 1H NMR: δ 0.86 (3H, t), 1.16-1.34 (22H, m), 1.35-1.59 (6H, m), 1.90-2.03 (4H, m), 2.52-2.68 (5H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 5.26-5.41 (2H, m), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-044, 1-arachidonoyl-lysergic acid diethylamide: 1H NMR: δ 0.86 (3H, t), 1.16-1.34 (10H, m), 1.35-1.49 (2H, m), 1.67-1.79 (2H, m), 1.90-2.06 (4H, m), 2.52-2.71 (11H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 5.28-5.45 (8H, m), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-045, 1-linoleoyl-lysergic acid diethylamide: 1H NMR: δ 0.86 (3H, t), 1.16-1.34 (16H, m), 1.35-1.59 (6H, m), 1.90-2.04 (4H, m), 2.52-2.69 (7H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 5.28-5.44 (4H, m), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-046, 1-(4-morpholinylbutyryl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.91-2.03 (2H, m), 2.40-2.72 (11H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m ), 3.52-3.67 (4H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.87- 7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-047, 1-(4-morpholinecarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.40 (5H, m), 3.48- 3.76 (8H, m), 4.03 (1H, dd), 6.15 (1H, d), 6.88-7.13 (2H, m), 7.55 (1H, ddd), 7.84 (1H, d). SYN-L-048, 1-(p-tosyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.83-3.07 (4H, m), 3.22-3.40 (5H, m), 4.04 (1H, dd), 5.09-5.19 (2H, m), 6.16 (1H, d), 6.97 (1H, dd), 7.11 (1H, dd), 7.29- 7.45 (5H, m), 7.61 (1H, ddd), 7.74 (1H, d). SYN-L-051, 1-(bicyclo[1.1.1]pentylcarbonyl)-lysergic acid diethylamide: 1H NMR: δ -0.15 - -0.02 (6H, m), 1.22 (6H, t), 2.19 (1H, m), 2.57 (3H, s), 2.81- 3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.16 (1H, d), 6.87-7.12 (2H, m), 7.52 (1H, ddd), 7.92 (1H, d). SYN-L-052, 1-(tetramethylcyclopropylmethanoyl)-lysergic acid diethylamide: 1H NMR: δ 0.88 (9H, s), 1.07-1.28 (9H, m), 2.43-2.62 (4H, m), 2.83-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.16 (1H, d), 6.87-7.13 (2H, m), 7.53 (1H, ddd), 7.98 (1H, d). SYN-L-054, 1-(L-valinyl)-lysergic acid diethylamide: 1H NMR: δ 1.16-1.65 (16H, m), 1.78 (1H, m), 2.52-2.72 (5H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.16 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-056, 1-(4-tetrahydropyranacetyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.60-1.85 (4H, m), 2.36 (1H, m), 2.52-2.73 (5H, m), 2.81-3.06 (4H, m), 3.22-3.40 (5H, m), 3.44-3.63 (4H, m), 4.00 (1H, dd), 6.16 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.93 (1H, d). SYN-L-057, 1-(quinuclidin-4-ylcarbonyl)-lysergic acid diethylamide: 1H NMR: δ 0.95-1.28 (18H, m), 2.09 (1H, m), 2.44 (1H, m), 2.57 (3H, s), 2.81- 3.07 (4H, m), 3.22-3.41 (5H, m), 4.00 (1H, dd), 6.01 (1H, d), 6.16 (1H, d), 6.95 (1H, dd), 7.11 (1H, dd), 7.34 (1H, ddd), 7.74 (1H, d). SYN-L-060, 1-isopropoxyacetate-lysergic acid diethylamide: 1H NMR: δ 1.06 (3H, t), 1.16-1.28 (9H, m), 2.57 (3H, s), 2.62-2.73 (2H, m), 2.82- 3.07 (4H, m), 3.18-3.30 (2H, m), 3.39 (1H, ddd), 4.02 (1H, dd), 4.34 (1H, m), 6.15 (1H, d), 6.85-7.12 (2H, m), 7.23 (1H, ddd), 7.92 (1H, d). SYN-L-066, 1-propionyl-lysergic acid 2,4-dimethylazetidide: 1H NMR: δ 1.00-1.16 (9H, m), 1.93 (2H, ddd), 2.57 (3H, s), 2.62-2.73 (2H, m), 2.82-3.08 (4H, m), 3.27 (1H, ddd), 3.83 (2H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.85-7.12 (2H, m), 7.23 (1H, ddd), 7.92 (1H, d). SYN-L-067, 1-(2-furoyl)-lysergic acid methylisopropylamide: 1H NMR: δ 1.15-1.27 (6H, m), 2.57 (3H, s), 2.77 (3H, s), 2.82-3.07 (4H, m), 3.33 (1H, m), 4.04 (1H, dd), 4.33 (1H, m), 6.15 (1H, d), 6.65 (1H, dd), 6.88-7.13 (2H, m), 7.30 (1H, dd), 7.54 (1H, ddd), 7.84 (1H, dd), 8.00 (1H, d). SYN-L-068, 1-(2-furoyl)-lysergic acid 2,4-dimethylazetidide: 1H NMR: δ 1.10 (6H, d), 1.93 (2H, m), 2.57 (3H, s), 2.82-3.08 (4H, m), 3.26 (1H, m), 3.81 (2H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.65 (1H, dd), 6.88-7.13 (2H, m), 7.30 (1H, dd), 7.54 (1H, ddd), 7.84 (1H, dd), 8.00 (1H, d). SYN-L-073, 1-propionyl-6-allyl-6-nor-lysergic acid methylisopropylamide: 1H NMR: δ 1.06 (3H, t), 1.15-1.27 (6H, d), 2.62-2.82 (5H, m), 2.82-3.11 (4H, m), 3.26-3.42 (3H, m), 3.97 (1H, dd), 4.33 (1H, m), 4.96-5.20 (2H, m), 5.71 (1H, m), 6.14 (1H, d), 6.86-7.12 (2H, m), 7.23 (1H, ddd), 7.96 (1H, d). SYN-L-074, 1-propionyl-6-allyl-6-nor-lysergic acid 2,4-dimethylazetidide: 1H NMR: δ 1.00-1.16 (9H, m), 1.93 (2H, m), 2.62-2.73 (2H, m), 2.82-3.11 (4H, m), 3.25-3.42 (3H, m), 3.76-4.04 (3H, m), 4.96-5.20 (2H, m), 5.71 (1H, ddt), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.23 (1H, ddd), 7.96 (1H, d). SYN-L-077, 1-cyclopropanecarbonyl-2-bromo-lysergic acid diethylamide: 1H NMR: δ 0.95-1.11 (4H, m), 1.22 (6H, t), 2.38-2.62 (4H, m), 2.92-3.12 (4H, m), 3.22-3.46 (5H, m), 4.07 (1H, dd), 6.13 (1H, d), 6.90-7.11 (2H, m), 7.29 (1H, dd). SYN-L-078, 1-(2-furoyl)-2-bromo-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.92-3.12 (4H, m), 3.22-3.45 (5H, m), 4.06 (1H, dd), 6.13 (1H, d), 6.65 (1H, dd), 6.96 (1H, dd), 7.10 (1H, dd), 7.22-7.36 (2H, m), 7.85 (1H, dd). SYN-L-079, 1-(3-phenylpropionyl)-2-bromo-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.35-1.78 (10H, m), 1.98 (1H, m), 2.52-2.70 (5H, m), 2.92-3.12 (4H, m), 3.22-3.38 (5H, m), 4.03 (1H, dd), 6.13 (1H, d), 6.87-7.09 (2H, m), 7.28 (1H, dd). SYN-L-140, 1-propionyl-2-fluoro-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.84-3.11 (4H, m), 3.18-3.42 (7H, m), 4.02 (1H, dd), 4.96-5.20 (2H, m), 5.71 (1H, m), 6.13 (1H, d), 6.65 (1H, dd), 6.88-7.13 (2H, m), 7.30 (1H, dd), 7.54 (1H, ddd), 7.84 (1H, dd), 8.00 (1H, d). SYN-L-191, 1-(pent-5-yn-1-oyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.44-2.63 (7H, m), 2.81-3.07 (4H, m), 3.22-3.43 (5H, m), 3.55 (1H, m), 4.02 (1H, dd), 5.98-6.20 (3H, m), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.98 (1H, d). SYN-L-193, 1-(3-thiomethylpropionyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.20 (3H, s), 2.57 (3H, s), 2.66-3.06 (8H, m), 3.22-3.40 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.24 (1H, ddd), 7.94 (1H, d). SYN-L-194, 1-(cyclopent-2-eneacetyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.62 (1H, m), 1.86 (1H, m), 2.13-2.38 (2H, m), 2.57 (3H, s), 2.69-2.81 (2H, m), 2.82-3.08 (5H, m), 3.22-3.43 (5H, m), 4.02 (1H, dd), 5.87 (1H, ddd), 6.08-6.20 (2H, m), 6.86-7.12 (2H, m), 7.23 (1H, ddd), 7.97 (1H, d). SYN-L-195, 1-acetyl-lysergic acid methylisopropylamide: 1H NMR: δ 1.15-1.27 (6H, d), 2.35 (3H, s), 2.57 (3H, s), 2.72-3.07 (7H, m), 3.33 (1H, m), 4.01 (1H, dd), 4.33 (1H, m), 6.15 (1H, d), 6.85-7.11 (2H, m), 7.22 (1H, ddd), 7.91 (1H, d). SYN-L-196, 1-acetyl-lysergic acid N-morpholinamide: 1H NMR: δ 2.35 (3H, s), 2.57 (3H, s), 2.82-3.06 (4H, m), 3.31 (1H, m), 3.54-3.71 (8H, m), 4.01 (1H, dd), 6.15 (1H, d), 6.85-7.11 (2H, m), 7.22 (1H, ddd), 7.91 (1H, d). SYN-L-197, 1-propionyl-lysergic acid ethylcyclopropylamide: (2H, m), 0.55-0.71 (2H, m), 1.06 (3H, t), 1.25 (3H, t), 2.57 m), 2.82-3.09 (5H, m), 3.29-3.43 (3H, m), 4.02 (1H, dd), (2H, m), 7.23 (1H, ddd), 7.92 (1H, d). lysergic acid-(S,S)-trans-2,5-dimethylpyrrolidide: 1H NMR: δ 1.00-1.18 (9H, m), 1.75-2.01 (4H, m), 2.57 (3H, s), 2.62-2.73 (2H, m), 2.82-3.08 (4H, m), 3.31 (1H, ddd), 3.76 (2H, m), 4.02 (1H, dd), 6.14 (1H, d), 6.85-7.12 (2H, m), 7.23 (1H, ddd), 7.92 (1H, d). SYN-L-200, 1-cyclopropanecarbonyl-lysergic acid-(S,S)-trans-2,5- dimethylpyrrolidide: 1H NMR: δ 0.87-1.04 (4H, m), 1.12 (6H, d), 1.76-1.99 (4H, m), 2.32 (1H, t), 2.57 (3H, s), 2.81-3.08 (4H, m), 3.24 (1H, m), 3.80 (2H, m), 3.96 (1H, dd), 6.13 (1H, d), 6.88-7.13 (2H, m), 7.54 (1H, ddd), 7.92 (1H, d). SYN-L-201, 1-propionyl-6-(2-fluoroethyl)-6-nor-lysergic acid diethylamide: 1H NMR: δ 1.06 (3H, t), 1.22 (6H, t), 2.62-2.73 (2H, q), 2.82-3.11 (6H, m), 3.22- 3.38 (5H, m), 4.02 (1H, dd), 4.34-4.45 (2H, m), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.23 (1H, ddd), 7.93 (1H, d). SYN-L-203, 1-propionyl-6-methallyl-6-nor-lysergic acid diethylamide: 1H NMR: δ 1.06 (3H, t), 1.22 (6H, t), 1.65 (3H, s), 2.62-2.73 (2H, q), 2.83-3.12 (4H, m), 3.18-3.38 (7H, m), 3.97 (1H, dd), 4.97-5.07 (2H, d), 6.14 (1H, d), 6.86- 7.12 (2H, m), 7.23 (1H, ddd), 7.96 (1H, d). SYN-L-204, 1-propionyl-6-cyclopropylmethyl-6-nor-lysergic acid diethylamide: 1H NMR: δ 0.22-0.38 (4H, m), 0.87 (1H, m), 1.06 (3H, t), 1.22 (6H, t), 2.36-2.48 (2H, d), 2.62-2.73 (2H, q), 2.82-3.11 (4H, m), 3.18-3.37 (5H, m), 3.99 (1H, dd), 6.14 (1H, d), 6.86-7.12 (2H, m), 7.23 (1H, ddd), 7.96 (1H, d). SYN-L-205, 1-(2-thiophenecarbonyl)-6-ethyl-6-nor-lysergic acid methylisopropyl- amide: 1H NMR: δ 1.01 (3H, t), 1.15-1.27 (6H, d), 2.59-2.70 (2H, q), 2.77 (3H, s), 2.85- 3.07 (4H, m), 3.28 (1H, ddd), 3.86 (1H, dd), 4.33 (1H, m), 6.15 (1H, d), 6.87- 7.12 (2H, m), 7.22 (1H, dd), 7.52 (1H, ddd), 7.79 (1H, dd), 7.92-8.04 (2H, m). SYN-L-206, 1-propionyl-2-methyl-lysergic acid diethylamide: 1H NMR: δ 1.05 (3H, t), 1.22 (6H, t), 2.47 (3H, s), 2.57 (3H, s), 2.62-2.73 (2H, q), 2.82-3.09 (4H, m), 3.22-3.40 (5H, m), 4.04 (1H, dd), 6.15 (1H, d), 6.86-7.22 (3H, m). SYN-L-208, 1-propionyl-2-cyclopropyl-lysergic acid diethylamide: 1H NMR: δ 0.97-1.28 (13H, m), 2.57 (3H, s), 2.63-2.74 (2H, q), 2.79-3.09 (5H, m), 3.22-3.41 (5H, m), 4.05 (1H, dd), 6.15 (1H, d), 6.93 (1H, dd), 7.04-7.26 (2H, m). SYN-L-209, 1-propionyl-2-trifluoromethyl-lysergic acid diethylamide: 1H NMR: δ 1.06 (3H, t), 1.22 (6H, t), 2.57 (3H, s), 2.63-2.74 (2H, q), 2.85-3.07 (4H, m), 3.22-3.43 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.95 (1H, dd), 7.09-7.37 (2H, m). SYN-L-210, 1-cyclopropanecarbonyl-9,10-cyclopropyl-lysergic acid diethylamide: 1H NMR: δ 0.86-1.08 (6H, m), 1.22 (6H, t), 1.44 (1H, m), 2.15 (1H, m), 2.57 (3H, s), 2.73-2.97 (5H, m), 3.22-3.40 (5H, m), 6.90-7.09 (2H, m), 7.47 (1H, ddd), 7.88 (1H, d). SYN-L-211, 1-propionyl-9,10-cyclopropyl-lysergic acid diethylamide: 1H NMR: δ 0.91-1.11 (5H, m), 1.22 (6H, t), 1.44 (1H, m), 2.57 (3H, s), 2.60 (2H, q), 2.71-3.00 (5H, m), 3.22-3.42 (5H, m), 6.90-7.08 (2H, m), 7.45 (1H, ddd), 7.75 (1H, d). SYN-L-212, 1-propionyl-9,10-dihydro-lysergic acid diethylamide: 1H NMR: δ 1.05 (3H, t), 1.22 (6H, t), 2.10 (1H, m), 2.39 (1H, m), 2.58 (3H, s), 2.60 (2H, q), 2.69-2.91 (4H, m), 2.96-3.16 (2H, m), 3.17-3.29 (4H, q), 3.36 (1H, m), 6.87-7.04 (3H, m), 7.73 (1H, d). SYN-L-213, 1-propionyl-6-ethyl-6-nor-lysergic acid 2,4-dimethylazetidide: (12H, m), 1.93 (2H, m), 2.59-2.73 (4H, m), 2.81-3.08 (4H, (2H, m), 3.96 (1H, dd), 6.16 (1H, d), 6.86-7.12 (2H, m), (1H, d). 6-ethyl-6-nor-lysergic acid 2-butyl amide: 1H NMR: δ 0.84 (3H, t), 0.95-1.11 (6H, t), 1.38 (3H, d), 1.53-1.66 (2H, m), 2.58- 2.73 (4H, m), 2.81-3.07 (4H, m), 3.34 (1H, m), 3.96 (1H, dd), 4.18 (1H, m), 6.15 (1H, d), 6.85-7.12 (2H, m), 7.23 (1H, ddd), 7.93 (1H, d). SYN-L-215, 1-propionyl-6-ethyl-6-nor-lysergic acid ethyl-(2-trifluoroethyl)- amide: 1H NMR: δ 0.95-1.11 (6H, t), 1.22 (3H, t), 2.58-2.73 (4H, m), 2.81-3.08 (4H, m), 3.20-3.37 (3H, m), 3.68-3.78 (2H, s), 4.00 (1H, dd), 6.15 (1H, d), 6.87-7.12 (2H, m), 7.23 (1H, ddd), 7.90 (1H, d). SYN-L-216, 1-(3,4-methylenedioxybenzoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.00 (1H, dd), 6.09-6.22 (3H, d), 6.85-7.11 (3H, m), 7.25 (1H, ddd), 7.57-7.78 (2H, m), 7.91 (1H, d). SYN-L-217, 1-(2-benzothiophenecarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.85-7.12 (2H, m), 7.26 (1H, ddd), 7.35-7.51 (2H, m), 7.89-8.10 (4H, m). SYN-L-218, 1-spirobicyclobutanoyl-lysergic acid diethylamide: 1H NMR: δ 1.16-1.48 (10H, m), 1.62-1.86 (4H, m), 2.14-2.35 (2H, m), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.16-3.43 (6H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.92 (1H, dd), 7.05 (1H, dd), 7.24 (1H, ddd), 7.97 (1H, d). SYN-L-219, 1-trifluoroacetyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.93 (1H, dd), 7.07 (1H, dd), 7.58 (1H, ddd), 8.12 (1H, d). SYN-L-220, 1-(N-pyrrolidine)acetyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.80-2.00 (4H, m), 2.57 (3H, s), 2.82-3.17 (8H, m), 3.22- 3.43 (5H, m), 3.81 (2H, s), 4.02 (1H, dd), 6.15 (1H, d), 6.92 (1H, dd), 7.05 (1H, dd), 7.25 (1H, ddd), 8.00 (1H, d). SYN-L-221, 1-thienothiophenecarbonyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.92 (1H, dd), 7.04 (1H, dd), 7.26 (1H, ddd), 7.56 (1H, dd), 7.72 (1H, dd), 7.96 (1H, d), 8.08 (1H, t). SYN-L-222, 1-(3-(trimethylsilyl)prop-2-ynoyl)-lysergic acid diethylamide: 1H NMR: δ 0.11 (9H, s), 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.41 (5H, m), 4.01 (1H, dd), 6.16 (1H, d), 6.93 (1H, dd), 7.06 (1H, dd), 7.56 (1H, ddd), 7.91 (1H, d). SYN-L-223, 1-(3-tetrahydropyrancarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.55-1.83 (3H, m), 2.07 (1H, m), 2.57 (3H, s), 2.82- 3.07 (4H, m), 3.22-3.64 (8H, m), 3.77 (1H, dd), 3.90-4.08 (2H, m), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.99 (1H, d). SYN-L-224, 1-(3-butenoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.46 (7H, m), 4.02 (1H, dd), 4.97-5.21 (2H, m), 6.03-6.22 (2H, m), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.97 (1H, d). SYN-L-225, 1-(tetrahydro-2-thiophenecarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.80 (1H, m), 1.89-2.10 (3H, m), 2.57 (3H, s), 2.82- 3.41 (11H, m), 4.02 (1H, dd), 4.56 (1H, dd), 6.15 (1H, d), 6.86-7.13 (2H, m), 7.26 (1H, ddd), 8.01 (1H, d). SYN-L-226, 1-(tetrahydro-3-furoyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 1.98 (1H, m), 2.25 (1H, m), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 3.59-4.12 (6H, m), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.24 (1H, ddd), 7.99 (1H, d). SYN-L-227, 1-(methylthio)acetyl-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.15 (3H, s), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22- 3.41 (5H, m), 3.95-4.08 (3H, m), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.25 (1H, ddd), 8.00 (1H, d). SYN-L-228, 1-(5-bromo-2-thiophenecarbonyl)-lysergic acid diethylamide: 1H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.00 (1H, dd), 6.15 (1H, d), 6.86-7.12 (2H, m), 7.40 (1H, d), 7.53 (1H, ddd), 7.83-8.02 (2H, m). SYN-L-229, 1-(1,2-dimethylcyclobutane-1-carbonyl)-lysergic acid diethylamide: 1H NMR: δ 0.96 (3H, d), 1.06-1.28 (9H, m), 1.62-2.00 (4H, m), 2.15 (1H, m), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.92 (1H, dd), 7.05 (1H, dd), 7.25 (1H, ddd), 7.99 (1H, d). SYN-L-230, 1-(1,4-dimethylspiro[2.3]hexane-1-carbonyl)-lysergic acid diethylamide: 1H NMR: δ 0.90-1.14 (5H, m), 1.22 (6H, t), 1.34 (3H, s), 1.46-1.76 (4H, m), 2.00 (1H, m), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.86-7.13 (2H, m), 7.55 (1H, ddd), 7.98 (1H, d). SYN-L-231, 1-(1,2-dimethylbicyclo[1.1.0]butane-2-carbonyl)-lysergic acid diethylamide: 1H NMR: δ 0.56 (1H, dd), 0.62-0.81 (2H, m), 1.16-1.33 (9H, m), 1.42 (3H, s), 2.57 (3H, s), 2.82-3.07 (4H, m), 3.22-3.41 (5H, m), 4.02 (1H, dd), 6.15 (1H, d), 6.93 (1H, dd), 7.13 (1H, dd), 7.56 (1H, ddd), 8.00 (1H, d). SYN-L-232, 1-(4-oxopentanoyl)-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 2.15 (3H, s), 2.57 (3H, s), 2.68-2.80 (2H, m), 2.82-3.07 (6H, m), 3.22-3.43 (5H, m), 4.01 (1H, dd), 6.15 (1H, d, J = 5.3 Hz), 6.92 (1H, dd), 7.05 (1H, dd), 7.23 (1H, ddd), 7.97 (1H, d). SYN-L-233, 1-(3-selenophenecarbonyl)-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.41 (5H, m), 4.01 (1H, dd), 6.15 (1H, d), 6.86-7.13 (2H, m), 7.53 (1H, dd), 7.54 (1H, ddd), 7.94 (1H, dd), 7.96 (1H, dd), 7.98 (1H, d). SYN-L-234, 1-(ferrocenecarbonyl)-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 2.44 (3H, s) 2.57 (3H, s), 2.81-3.07 (4H, m), 3.22-3.41 (5H, m), 4.01 (1H, dd), 4.23 (5H, s), 4.53 (2H, m), 4.82 (2H, m), 6.15 (1H, d), 6.91 (1H, dd), 7.02 (1H, ddd), 7.04 (1H, dd), 7.85 (1H, d). SYN- L-235, 1-(ferrocenecarbonyl)-6-allyl-6-nor-lysergic acid diethylamide: 1 H NMR: δ 1.22 (6H, t), 2.44 (3H, s) 2.82-3.11 (4H, m), 3.18-3.42 (7H, m), 3.96 (1H, dd), 4.96-5.20 (2H, m), 5.71 (1H, ddt), 4.23 (5H, s), 4.53 (2H, m), 4.82 (2H, m), 6.15 (1H, d), 6.91 (1H, dd), 7.03 (1H, ddd), 7.04 (1H, dd), 7.85 (1H, d). Compounds of the invention act as prodrugs Male C57BL/6J mice (6-8 weeks old) obtained from Jackson Laboratories (Bar Harbor, ME, USA) were housed in a vivarium at the University of California San Diego (UCSD), an AAALAC-approved animal facility that meets all Federal and State requirements for care and treatment of laboratory animals. Mice were housed up to four per cage in a climate-controlled room on a reverse-light cycle (lights on at 1900 h, off at 0700 h) and were provided with ad libitum access to food and water, except during behavioral testing. Testing was conducted between 1000 and 1800 h. All animal experiments were carried out in accordance with NIH guidelines and were approved by the UCSD animal care committee. To prepare the drug solutions, a stock solution of each lysergamide was prepared (1 mg lysergamide was dissolved in 100 μl DMSO) and stored at -20 °C. On the day of each experiment, the stock solution was diluted into sterile saline at a concentration of 0.2 mg/ml. Solutions used for administration to mice were prepared fresh daily. Blood samples were taken from mice injected with 1 mg/kg of the test compound IP, with a 30 min pretreatment time. The vehicle was sterile saline, 5 ml/kg injection volume. All of the drugs were dissolved in a DMSO stock solution (0.1 ml added per mg) and then diluted into saline. Blood was collected in tubes coated with K2EDTA. Within 30 min of collection, the blood was centrifuged (2,000 rpm) for 12 min at 4 °C, and then plasma was collected in 50-µl aliquots, flash frozen with dry ice, and stored at -80 °C. Samples were tested with LCMS to determine concentration of LSD released at the 30 min time point. Values are average of 3 samples taken from different mice. Sample preparation by solid-phase extraction: Sample preparation was performed as described previously by Halberstadt et al. (Halberstadt AL, Chatha M, Klein AK, McCorvy JD, Meyer MR, Wagmann L, Stratford A, Brandt SD (2020) Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology 172: 107856. DOI: 10.1016/j.neuropharm.2019.107856), with minor modifications. 10 μl of methanolic LSD-d3 (as internal standard, final plasma concentration 5 ng/ml) were added to 0.1 ml of mouse plasma, diluted with 2.9 ml of purified water, mixed for 15 s on a rotary shaker, and loaded on a HCX cartridge (130 mg, 3 ml) previously conditioned with 1 ml of methanol and 1 ml of purified water. After extraction, the cartridge was washed with 1 ml of purified water, 1 ml of 0.01 M aqueous hydrochloric acid, and 2 ml of methanol. Reduced pressure was applied until the cartridge was dry and the analytes were eluted with 1 ml of a freshly prepared mixture of methanol-aqueous ammonia (98:2, v/v) into a reaction tube. The eluate was evaporated to dryness under a stream of nitrogen at 70 °C and the residue was dissolved in 25 μl of a mixture of 10 mM aqueous ammonium formate- acetonitrile (1:1, v/v) containing 0.1% formic acid. The LSD plasma concentration was determined using an LC-ion trap MS apparatus and an LC-high-resolution MS/MS apparatus by calculating the mean value of both analyses. LC-ion trap MS apparatus for LSD quantification: Samples were analyzed using a ThermoFisher Scientific (TF, Dreieich, Germany) LXQ linear ion trap MS, coupled to a TF Accela ultra high performance LC (UHPLC) system consisting of a degasser, a quaternary pump, and an autosampler. Gradient elution was performed on a TF Hypersil GOLD C18 column (100 mm × 2.1 mm inner diameter, 1.9 μm particle size). The mobile phase consisted of 10 mM aqueous ammonium formate plus 0.1% formic acid (pH 3.4, eluent A) and acetonitrile plus 0.1% formic acid (eluent B). The flow rate was set to 0.5 ml/min and the following gradient was used: 0– 2.0 min 2% B, 2.0–4.0 min to 80% B, 4.0–6.0 min hold 80% B, 6.0–6.5 min to 90% B, 6.5–7.0 min hold 90% B, 7.0-10.0 min hold 80% B, 10.0-17.0 hold 2% B. Analyses were performed in a targeted acquisition mode with an inclusion list, where MS2 spectra of given precursor ions (LSD and LSD-d3) were recorded. The injection volume was 10 μl each. The MS was equipped with a heated electrospray ionization II (HESI-II) source, other conditions were as follows: positive ionization mode; sheath gas, nitrogen at flow rate of 34 arbitrary units (AU); auxiliary gas, nitrogen at flow rate of 11 AU; vaporizer temperature, 250 °C; source voltage, 3.00 kV; ion transfer capillary temperature, 300 °C; capillary voltage, 38 V; tube lens voltage, 110 V; automatic gain control (AGC) target, 5,000 ions for MS2; data type, centroid; normalized collision energy, 35.0; wideband activation, enabled; isolation width, m/z 1.5. TF Xcalibur Qual Browser software version 2.0.7 was used for data evaluation and LSD concentration was determined comparing the peak areas of LSD and LSD-d3 within the same run. LC-high resolution MS/MS apparatus for LSD quantification: Analyses were performed using the procedure of Wagmann et al. (HH, Meyer MR (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem 411: 4751-4763. DOI: 10.1007/s00216-018-1558-9), with minor modifications. A TF Dionex UltiMate 3000 Rapid Separation (RS) UHPLC system with a quaternary UltiMate 3000 RS pump and an UltiMate 3000 RS autosampler was used, controlled by the TF Chromeleon software version 6.80, and coupled to a TF Q-Exactive Plus equipped with a HESI-II source. Mass calibration was performed prior to analysis according to the manufacturer’s recommendations using external mass calibration. Gradient elution was performed on a TF Accucore PhenylHexyl column (100 mm × 2.1 mm inner diameter, 2.6 μm particle size). The mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid (0.1%, v/v) and acetonitrile (1%, v/v, pH 3, eluent A) and 2 mM ammonium formate in acetonitrile/methanol (50:50, v/v) containing formic acid (0.1%, v/v) and water (1%, v/v, eluent B). The gradient and flow rate were programmed as follows: 0– 10 min 10% B to 50% B, 10–12 min hold 98% B, and 12–14 min hold 10% B, constantly at a flow rate of 0.5 mL/min. HESI-II source conditions were as follows: heater temperature, 438 °C; ion transfer capillary temperature, 269 °C; sheath gas, 53 AU; auxiliary gas, 14 AU; sweep gas, 3 AU; spray voltage, 3.50 kV, and S-lens RF level, 60.0. Mass spectrometric analysis was performed in positive full- scan mode and targeted MS2 mode using an inclusion list containing the accurate masses of protonated LSD and LSD-d3. The injection volume was 5 μL each. The settings for full-scan data acquisition were as follows: resolution, 35,000; AGC target, 1e6; maximum injection time (IT), 120 ms; scan range, m/z 100–700. The settings for the targeted MS2 were as follows: resolution, 17,500; AGC target, 2e5; maximum IT, 250 ms; isolation window, m/z 1.0; high-collision dissociation cell with stepped normalized collision energy 17.5, 35.0, 52.5. TF Xcalibur Qual Browser software version 2.2 SP1.48 was used for data evaluation and the LSD concentration was determined comparing the peak areas of LSD and LSD-d3 within the same run. All lysergamides tested were hydrolyzed to LSD after IP injection in mice. Each lysergamide was administered at an IP dose of 1 mg/kg and plasma samples were collected 30 min later. LSD was quantified using LSD-d3 as an internal standard. Plasma levels of LSD ranged from 14.5 ± 3.0 for SYN-L-006, up to 186.7 ± 5.5 ng/ml (mean ± SEM) for SYN-L-027 as shown in Table 1. Table 1: The results are further depicted in Figure 1. The efficiency of conversion to LSD across the 12 drugs was calculated by normalizing the results based on the molar mass of each drug that was injected. Figure 2 shows the data after normalization; the conversion efficacy of each compound is shown as ng/ml LSD in plasma per μmol/kg injected. SYN-L-036 showed the highest conversion efficiency, with 126.0 ± 8.6 ng/ml LSD generated per μmol/kg of drug injected. Compounds of the invention produce a head-twitch response in mice A head-twitch response (HTR) study was conducted in male C57BL/6J mice to assess whether the lysergamides can induce 5-HT2A receptor activation in vivo. Each lysergamide was tested at an IP dose of 1 mg/kg. The results of are summarized in Figure 3. There was a significant main effect of drug in the experiment (F(12,62) = 33.00, p < 0.0001). Post-hoc pairwise comparisons confirmed that all nine of the lysergamides tested in the experiments induced a significant increase of HTR counts compared to vehicle control. A correlation analysis was conducted to evaluate the relationship between drug effects on the HTR and LSD plasma concentrations. The magnitude of the HTR induced by each drug was calculated by subtracting the baseline level of HTR (measured using the vehicle group) from the drug responses. The HTR was assessed using a head-mounted magnet and a magnetometer detection coil. The mice were anesthetized with ketamine and xylazine, a small incision was made in the scalp, and a small neodymium magnet was attached to the dorsal surface of the cranium using dental cement. Following a recovery period of several weeks, HTR experiments were carried out in a well-lit room. Ten groups of male C57BL/6J mice were injected IP with vehicle (n = 18) or 1 mg/kg of each lysergamide (n=5 mice/group, 45 total). The injection volume was 5 ml/kg. The mice were immediately placed in a HTR recording chamber and activity was recorded continuously for 30 min. Coil voltage was low-pass filtered (1 kHz cutoff frequency), amplified, digitized (20 kHz sampling rate, 16-bit ADC resolution), and saved to disk using a Powerlab/8SP data acquisition system with LabChart software ver. 7.3.2 (ADInstruments, Colorado Springs, CO, USA). Head twitches were identified using a validated technique based on artificial intelligence (Halberstadt AL (2020) Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network. Sci Rep 10: 8344). To detect the behavior, events in the recordings are transformed into a visual representation in the time-frequency domain (a scalogram), deep features are extracted using the pretrained convolutional neural network (CNN) ResNet-50, and then the images are classified using a Support Vector Machine (SVM) algorithm. Head-twitch counts were analyzed using one-way analyses of variance (ANOVA). Post hoc comparisons were made using Dunnett’s test. Significance was demonstrated by surpassing an α level of 0.05. The results are summarized in Figures 3 and 4. Compounds of the invention show attenuated activity compared to ALD-52 in humans Compounds of the invention were tested on volunteers who were experienced with the use of the related compound ALD-52. For each compound, a solution was prepared by dissolving the tartrate salt in deionized water to produce a concentration either of 1 mg/ml of the tartrate salt, or calculated to be equivalent to 1 mg/ml of the free base. This was either administered directly, or was prepared into standardised dosage units by pipetting 0.1 ml of solution onto a square of perforated blotter paper, which was placed overnight in a desiccator and allowed to evaporate to dryness. The results are shown in Table 2. Certain compounds of the invention exhibit attenuated psychedelic effects compared to ALD-52, and may be useful for psychedelic-assisted psychotherapy but with reduced hallucinogenic side effects compared to commonly used agents such as LSD or psilocybin. Certain other compounds of the invention produce no psychedelic effects at any dose tested, but exhibit useful anti-headache properties. Table 2: Compounds of the invention alleviate cluster headache symptoms in humans Eighteen volunteers were recruited through cluster headache support groups in the Netherlands. Age range of volunteers was between 23 to 67 (average 45.17), 14 males and 4 females. All volunteers had previous experience using psychedelic drugs such as LSD or psilocybin to alleviate cluster headache attacks, as well as prescribed medications including verapamil, prednisone, sumatriptan, topiramate and indomethacin. Volunteers were asked to discontinue use of prescribed medications for five days preceding the commencement of the study and for the eight-week duration. Participants were supplied standardised 3.0 mg dosage units of SYN-L-017 as the tartrate salt (equivalent to 2.58 mg of SYN-L-017 freebase), measured into capsules for oral administration. These were tested as a preventative for chronic cluster headache attacks. One 3 mg capsule was administered intermittently in a pattern of one day on, two days off for a period of eight weeks (using the protocol described in Karst et al. (Karst M, et al. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non- randomized case series. Cephalalgia 2010; 30(9):1140-1144. DOI: 10.1177/0333102410363490)) and the volunteers were asked to keep a diary to track the frequency and self-rated severity of cluster headache attacks on a scale of 1-10. At the start of the study, baseline severity of cluster headache attacks was rated at an average of 8.78 / 10 with an average of 3.44 attacks per day. After four weeks, severity was rated at an average of 4.46 / 10 with an average of 2.13 attacks per day. At the end of the eight weeks this had dropped to an average severity of 3.72 / 10 with an average of 1.78 attacks per day. Overall, 91.67 % of volunteers reported improvement of cluster headache symptoms when taking SYN-L-017, with attacks perceived as being less frequent, of shorter duration and of reduced intensity compared to baseline. 75 % of volunteers reported no side effects of any significance while 25 % reported side effects including dizziness, nausea, fatigue, difficulty concentrating and insomnia. In all cases these were perceived as being mild and no volunteers reported side effects rated as moderate or severe. No side effects consistent with psychedelic effects were reported. 83.33 % of volunteers thought SYN-L-017 was more effective than the prescribed medication they normally used to alleviate cluster headache attacks.